Core Viewpoint - Medtronic reported a stable revenue growth of 3.6% year-on-year for FY2025, with a total revenue of $33.5 billion, and a significant increase in net profit by 31% to approximately $4.66 billion, indicating strong operational performance despite potential tariff impacts [5][19]. Financial Performance - For FY2025, Medtronic's total revenue reached $33.5 billion, reflecting a 3.6% year-on-year growth, with organic growth at 4.9% [5][19]. - The net profit attributable to shareholders was approximately $4.66 billion, with a GAAP diluted earnings per share of $3.61, marking a 31% increase year-on-year [5][19]. - Adjusted operating margin improved to 27.8%, up by 0.9 percentage points from the previous year [5]. Segment Performance - **Cardiovascular Segment**: Generated approximately $12.48 billion in revenue, a year-on-year increase of 6%, driven by strong demand for minimally invasive devices [8]. - **Neuroscience Segment**: Achieved around $9.85 billion in revenue, growing approximately 5%, with significant contributions from spinal and neurostimulation products [9]. - **Medical Surgical Segment**: Reported revenue of about $8.41 billion, remaining stable with a slight organic increase of 0.8% [10]. - **Diabetes Segment**: Revenue reached $2.755 billion, showing a robust growth of over 10%, supported by the adoption of new insulin pumps and continuous glucose monitoring systems [11]. Business Split - Medtronic announced plans to spin off its diabetes business into a separate publicly traded company to optimize its business portfolio and focus on higher-margin segments [12][18]. - The split is expected to be completed within approximately 18 months, with the new diabetes company retaining all assets, product lines, and approximately 8,000 employees [15][18]. - The split aims to enhance the focus on high-profit growth areas for Medtronic while allowing the new diabetes entity to concentrate on innovations in insulin delivery and monitoring technologies [18]. Future Outlook - Medtronic provided cautious guidance for FY2026, expecting organic revenue growth of about 5%, with diluted earnings per share projected between $5.50 and $5.60, slightly below Wall Street expectations [19]. - The guidance reflects uncertainties regarding potential tariff changes, with management indicating that higher tariffs could increase product costs by $200 million to $350 million [19].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年5月22日， 博音听力 宣布完成B轮 数千万元 增资。本轮融资由苏州国发创业投资控股有限公司 领投，资金将主要用于加大国产助听器研发投入及专业服务机构布局，进一步开拓听力生态新格局。 值得一提的是， 今年年初 博音听力刚刚完成 近亿元 B轮融资 ，由广州产投与曜金资本联合领投。 # 产品介绍 博音听力的主打产品包括 唐潮系列助听器、博音骨导式助听器和智能蓝牙助听器，以及针对重度/极重度听损 人群的秦风和汉韵系列耳背式助听器 。 2023年，博音听力自主研发的"唐潮"系列定制助听器获得了上市批 准；紧接着在2024年，"秦风"系列和"汉韵"系列耳背式助听器也相继获批上市，不断丰富着产品线。 以下是这些产品的特点和技术创新： 唐潮系列助听器 博音骨导式助听器 智能蓝牙助听器 秦风和汉韵系列耳背式助听器 包含定制式助听器和耳背机，如唐潮真爱、舒听系列； 搭载全数字云听平台， ...

Core Viewpoint - The article highlights the significant advancements in cardiac electrophysiology technology, particularly focusing on the launch of the StarTrek® system by Jianhu Medical, which represents a breakthrough in domestic electrophysiology solutions [2][8]. Group 1: Industry Overview - Atrial fibrillation (AF) is the most common arrhythmia, affecting nearly 20 million patients in China, yet the number of surgical procedures remains low compared to coronary interventions [7]. - The market for three-dimensional mapping technology has evolved significantly, with major players like Johnson & Johnson and Abbott dominating the field, creating a monopolistic environment [7][8]. Group 2: Product Introduction - The StarTrek® system is the first domestic open three-dimensional dielectric imaging mapping system, integrating imaging, mapping, navigation, and damage assessment [8][10]. - The system offers high precision with a positioning accuracy of 0.4 mm and stability of 0.1 mm, significantly reducing the time required for mapping compared to traditional methods [14]. Group 3: Clinical Performance - In clinical trials, the StarTrek® system demonstrated lower pain responses and no adverse events during procedures for drug-resistant paroxysmal atrial fibrillation [10]. - The system allows for real-time observation of myocardial conditions and damage assessment during ablation, enhancing the success rate of procedures [14]. Group 4: Company Background - Jianhu Medical was founded in 2021, led by a team with extensive experience from major medical device companies, focusing on integrated solutions for cardiac electrophysiology [31]. - The company has developed both three-dimensional dielectric mapping technology and nanosecond pulsed electric field ablation technology, positioning itself uniquely in the market [31]. Group 5: Competitive Landscape - Other notable players in the three-dimensional mapping system market include Boston Scientific, Medtronic, and Abbott, each with their own innovative products and technologies [16][18][20][23]. - The competitive landscape is characterized by continuous technological advancements and regulatory approvals, with several systems recently gaining market entry [22][25][27][29].

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年4月25日，市场监管总局（国家标准委）发布国家标准 《心血管植入器械 人工心脏瓣膜 第3部分：经导管植入式人工心脏瓣膜》（GB/T 12279.3—2025） ， 该标准将于2026年5月1日正式实施。 这是我国 首个针对经导管植入式人工心脏瓣膜（TAVR）产品的国家级标准， 填补了高风险结构性心脏介入器械在国家标准层面的空白。标准由全国医用植入器械 标准化技术委员会归口，修改采用ISO 5840-3，体现了"国际接轨+本土适配"的技术路线。 与此同时，经导管介入整体市场呈现出快速增长态势。据 弗若斯特沙利文 数据显示，2023年中国心血管介入器械市场规模已达501亿元，预计2025年将达到570亿 元。受益于老龄化进程加快、心血管疾病发病率持续上升，以及微创手术技术的广泛普及，市场需求仍在不断释放。 政策层面 ，国家正在持续推进高值耗材集采改革，鼓励创新器械的临床转 ...

即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 近日，美国食品药品监督管理局（FDA）宣布， 到2025年6月底前将在全机构范围内部署生成式人工智 能（generative AI）系统 ，并整合进其内部数据平台，所有中心统一迁移至同一AI系统。由此，这一 全球最具权威的医药监管机构，正式按下了监管智能化的"快进键"。 与其说这是技术转型，不如说是制度进化的一部分。本文将从监管视角出发，解析FDA此举背后的战略 意图、关键角色、全球对比，并思考中国如何看待这一转变。 这一次，FDA"动真格"了 01 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 2025年5月8日，FDA局长Martin Makary宣布，要求所有监管中心在6月30日前 全面接入统一的生成式AI系 统，用于审评流程中各类辅助任务 。此举并非出于概念试水，而是基于近期一项试点项目的积极反馈：在药 品审评中，AI协助处理化学、生产和质量控制（CMC）资料，显著提升了效率和一致性，一位审评专家直 言，"过去三天 ...

Core Viewpoint - The article highlights the recent advancements and product launches by Bausch + Lomb in the field of ophthalmology, particularly focusing on the LuxLife IOL, which has received CE certification and is set to expand into various global markets [1][2][4]. Product Launches and Innovations - Bausch + Lomb announced the CE certification of its LuxLife all-distance intraocular lens (IOL), which features pure refractive optical (PRO) technology and combined ray (ART) technology for natural, continuous vision from distance to near [1][4]. - The LuxLife IOL is designed with a pre-loaded feature and a dual-injection system, enhancing surgical flexibility and precision [4][5]. - The PRO technology allows for continuous and uniform refraction of light, avoiding light loss associated with traditional diffractive IOLs [5]. - The ART technology optimizes light propagation paths, improving mid-distance visual clarity and reducing glare and halos, with clinical studies showing 95.6% of patients not needing glasses for mid-distance and 89.5% for near distance [6]. Financial Performance - In Q1 2025, Bausch + Lomb reported revenues of $1.137 billion, with a net loss of $212 million [20]. - The Vision Care segment generated $656 million, reflecting a 5% increase compared to Q1 2024, driven by sales of silicone hydrogel lenses and over-the-counter dry eye products [20][21]. - The Surgical segment's revenue increased to $214 million from $197 million in the previous year, while the Pharmaceuticals segment remained stable at $267 million [21]. - The company raised its full-year revenue guidance to $5 billion to $5.1 billion, with an adjusted EBITDA forecast of $850 million to $900 million [22].

| 思宇年度活动回顾： | 首届全球眼科大会 | 首届全球骨科大会 首届全球心血管大会 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 即将召开： | | | | | | | | | 2025年6月12日，首届全球医美科技大会 | | | | | | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | | | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | | | | | | | 2025年5月20日 ， | 医疗器械介入巨头 | 麦瑞通（Merit Medical Systems, Inc.） | 宣布完成对 | Biolife Delaware, LLC 的全资收购 | 。交易金额为 | 1.2亿美元 | （约合8.6亿人 | Biolife总部位于美国佛罗里达州，专注于局部止血和创口管理产品，其核心品牌 StatSeal 和 WoundSeal 被广泛应用于手术、介入治疗和急救场景。本次并购是麦瑞 通一年内完成的第三笔重要交易，标志着其在 术后护理领域 的进一步战略深化。 # ...

| 思宇年度活动回顾： 首届全球眼科大会 首届全球骨科大会 首届全球心血管大会 | | --- | | 即将召开： | | 2025年6月12日，首届全球医美科技大会 | | 2025年7月17日，第二届全球医疗科技大会 | | 2025年9月4-5日，第三届全球手术机器人大会 | 2025年5月15日， 专注于脑瘤治疗技术开发的临床阶段公司 Alpheus Medical 宣布完成 5200万美元 （约合3.8亿人民币）B轮融资 ，本轮融资由 HealthQuest Capital 和 Samsara BioCapital 联合领投， OrbiMed、Action Potential Venture Capital、BrightEdge（美国癌症学会）、Brain Tumor Investment Fund（国家脑瘤学会）与 Sontag 基金 会 等多家机构共同参与。 公司表示， 融资所得将用于推进 其声动力疗法（Sonodynamic Therapy, SDT）平台在脑肿瘤领域的临床开发 ，特别是即将启动的 Phase 2B 随机对照试验，并进一步 扩展适应症和技术平台，同时将继续与监管机构沟通，为 2 ...

Core Viewpoint - Prevencio's innovative AI-based blood test HART CADhs has received FDA breakthrough device designation, promising to enhance early diagnosis and intervention for obstructive coronary artery disease [2][3]. Group 1: Product Overview - HART CADhs is the only AI-based multi-protein blood test for cardiovascular assessment, designed to identify the presence of obstructive coronary artery disease through a simple blood sample [8][10]. - The test utilizes advanced AI algorithms to analyze multiple cardiac biomarkers, achieving an accuracy rate of 86% [10]. - It assesses three proteins: high-sensitivity troponin, adiponectin, and kidney injury molecule-1, along with clinical parameters like age, gender, and history of invasive cardiac interventions [10]. Group 2: Clinical Significance - Obstructive coronary artery disease is the most common type of coronary heart disease, often leading to severe outcomes like heart attacks and sudden death [4][7]. - Current diagnostic methods have limitations in accuracy and accessibility, particularly in areas lacking cardiac specialists [7][12]. - HART CADhs addresses these challenges by providing a non-invasive, rapid, and AI-driven diagnostic tool, which is crucial for improving early diagnosis and intervention [8][12]. Group 3: Future Prospects - Prevencio plans to transition HART CADhs from a laboratory-developed test to an FDA-approved in vitro diagnostic product, potentially reducing report turnaround time to one hour [12]. - The company aims to expand the use of HART CADhs into emergency care settings, enhancing early and accurate diagnosis for a broader patient population [13][14]. Group 4: Company Background - Prevencio, headquartered in Washington, is a leading AI medical blood testing company focused on early diagnosis and precision medicine for major diseases, including cardiovascular conditions [14]. - The company has developed seven blood testing products based on its HART platform, with significant research published in reputable journals [14].

Core Viewpoint - The deadline for the 2025 Global Aesthetic Technology Innovation Awards has been extended to May 26, 2025, to allow more time for participants to prepare their submissions and showcase their innovations in the medical aesthetics field [1][2]. Group 1: Event Details - The event will take place on June 12, 2025, at the Beijing Zhongguancun Exhibition Center, with an expected attendance of 500 participants from various sectors including government, hospitals, and investment institutions [1]. - The conference will gather clinical experts, top scientists, technology innovators, and regulatory bodies to discuss cutting-edge developments, commercialization paths, regulatory trends, and market opportunities in the medical aesthetics industry [1][3]. Group 2: Award Categories - The awards include the 2025 Global Aesthetic Technology Innovation Award, aimed at companies and manufacturers that have made significant technological innovations in medical aesthetics [5]. - The 2025 Global Aesthetic Clinical Excellence Award recognizes products or technologies that have achieved notable results in clinical applications, receiving positive feedback from both doctors and patients [6]. - The 2025 Global Aesthetic Industry Service Award honors companies and institutions providing exceptional services in areas such as technology innovation, clinical trials, and production [7]. - The 2025 Global Aesthetic Innovation & Translation Award is for individuals who have made outstanding contributions to innovation in medical aesthetics, promoting products or solutions with industrialization potential [8]. Group 3: Evaluation Process - The evaluation will be conducted through expert reviews and meetings [9]. - The submission phase is open until May 26, 2025, followed by a review and selection process from May 27 to June 2, 2025, with winners notified between June 3 and June 6, 2025 [12].